Abstract:Arteriosclerosis, Thrombosis, and Vascular Biology, Ahead of Print. BACKGROUND:BMS-986141 is a novel potent highly selective antagonist of PAR (protease-activated receptor) type 4. PAR4 antagonism has been demonstrated to reduce thrombus formation in isolation and in combination with factor Xa inhibition in high shear conditions in healthy people. We sought to determine whether PAR4 antagonism had additive antithrombotic effects in patients with coronary artery disease who were receiving antiplatelet therapy.METHODS:Forty-five patients with stable coronary heart disease and 10 healthy volunteers completed a phase 2a open-label 4-arm single-center study. Patients were allocated to 1 of 3 treatment arms for 7 days: (1) ticagrelor (90 mg BID), (2) aspirin (75 mg QD), or (3) the combination of ticagrelor and aspirin. Agonist-induced platelet aggregation, platelet activation, and ex vivo thrombus formation were measured before and 2 and 24 hours after a single oral 4-mg dose of BMS-986141 on the first study visit day in all participants.RESULTS:BMS-986141 demonstrated highly selective inhibition of PAR4-AP (agonist peptide)–induced platelet aggregation, P-selectin expression, and platelet-monocyte aggregate expression (P≤0.001 for all), which were unaffected by concomitant antiplatelet therapies. PAR4 antagonism reduced ex vivo thrombus area in high shear conditions in healthy volunteers (−21%;P=0.001) and in patients receiving ticagrelor alone (−28%;P=0.001), aspirin alone (−23%;P=0.018), or both in combination (−24%;P≤0.001). Plasma concentration of BMS-986141 correlated with PAR4-AP–induced platelet responses (P≤0.001 for all) and total thrombus area under high shear stress conditions (P≤0.01 for all).CONCLUSIONS:PAR4 antagonism has additive antithrombotic effects when used in addition to ticagrelor, aspirin, or their combination, in patients with stable coronary heart disease.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifier: NCT05093790.

Synthesis and Evaluation of Novel and Potent Protease Activated Receptor 4 (PAR4) Antagonists Based on a Quinazolin-4(3H)-one Scaffold.

Discovery of quinazoline-benzothiazole derivatives as novel potent protease-activated receptor 4 antagonists with improved pharmacokinetics and low bleeding liability

Discovery of Potent and Selective Quinoxaline-Based Protease-Activated Receptor 4 (PAR4) Antagonists for the Prevention of Arterial Thrombosis

Protease activated receptor 4 (PAR4) antagonists: Research progress on small molecules in the field of antiplatelet agents

Inhibitors of Protease-Activated Receptor 4 (PAR4): a Review of Recent Patents (2013-2021).

Synthesis and Antiplatelet Activity of Ethyl 4-(1-benzyl-1h-indazol-3-yl)benzoate (YD-3) Derivatives.

Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021)

Discovery of 2,3-Dihydro[1,4]dioxino[2,3- g ]benzofuran Derivatives as Protease Activated Receptor 4 (PAR4) Antagonists with Potent Antiplatelet Aggregation Activity and Low Bleeding Tendency

Discovery of Potent Orally Active Protease-Activated Receptor 1 (par1) Antagonists Based on Andrographolide

Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives As Potent and Selective P21-Activated Kinase 4 (PAK4) Inhibitors

Development of a Series of (1-Benzyl-3-(6-methoxypyrimidin-3-yl)-5-(trifluoromethoxy)-1h-indol-2-yl)methanols As Selective Protease Activated Receptor 4 (PAR4) Antagonists with in Vivo Utility and Activity Against Γ-Thrombin.

Discovery of 7, 4-dimethoxy-3-hydroxyflavone as a protease-activated receptor 4 antagonist with antithrombotic activity and less bleeding tendency in mice

Synthesis and Biological Evaluation of BMS-986120 and Its Deuterated Derivatives As PAR4 Antagonists.

PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies

Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog

Research progress on thrombin receptorantagonists

1-Oxo-3,4-dihydroisoquinoline-4-carboxamides as novel druglike inhibitors of poly(ADP-ribose) polymerase (PARP) with favourable ADME characteristics

Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy

Structure-based QSAR, Molecule Design and Bioassays of Protease-Activated Receptor 1 Inhibitors

Design, Synthesis and Evaluation of Novel 2-Amino-3-(naphth-2-yl)propanoic Acid Derivatives As Potent Inhibitors of Platelet Aggregation

Design, Synthesis and Evaluation of 1,4-Benzodioxine Derivatives As Novel Platelet Aggregation Inhibitors.